This excerpt taken from the ELN 6-K filed Sep 29, 2009.
judgment against us.
We and some of our officers and directors have been named as defendants in putative class actions filed in 2008. These actions have been consolidated. The consolidated class action complaint alleges claims under the U.S. federal securities laws. The complaint alleges that we caused the release of materially false or misleading information regarding bapineuzumab. The complaint seeks damages and other relief that the courts may deem just and proper. Adverse results in these lawsuits or any litigation to which we are a party could have a material adverse effect on us.